NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Saturday, March 5, 2005

While most drugmakers have stepped in to make their HIV treatments available to developing countries at no-profit prices, they have not been willing to sign on to schemes that put at risk profits in first-world markets that should have the ability to fund the expensive R&D enterprise that produces these drugs. This has often put drugmakers at odds with international groups, like the WHO, which have been eager to give away today’s medicines with scarce regard to what it does to the incentives that keep investment capital flowing into new development.
Full story here.